FDA grants accelerated approval to Bizengri, a breakthrough therapy for advanced lung and pancreatic cancer, marking the seventh approval under the National Priority Voucher Pilot Program.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
Seventh Approval under National Prior Drug approval milestone
Lung And Pancreatic Cancer Cancer types treated
2.8 months Fastest patient response
12.9 months Longest patient response
2.8 Months fastest response time
12.9 Months longest response time
7 seventh approval under program